Skip to main content
Skip to footer
Opens in a new tab
About
Our Philosophy
Meet Our Care Team
Your Care Experience
Services
Cancer Care
Laboratory Services
Same-Day CT Imaging
Liberty Pharmacy
Infusion Services
Clinical Trials
Is a Clinical Trial Right for Me?
Find a Clinical Trial
Frequently Asked Questions
About PhaseWell Research
Resources
Patient Resources
Patient Forms
Billing & Insurance
Educational Resources
Approved Oncology Drugs (PDF)
Referring Physicians
Contact Us
About
Our Philosophy
Meet Our Care Team
Your Care Experience
Services
Cancer Care
Laboratory Services
Same-Day CT Imaging
Liberty Pharmacy
Infusion Services
Clinical Trials
Is a Clinical Trial Right for Me?
Find a Clinical Trial
Frequently Asked Questions
About PhaseWell Research
Resources
Patient Resources
Patient Forms
Billing & Insurance
Educational Resources
Approved Oncology Drugs (PDF)
Referring Physicians
Contact Us
Category:
Colon
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer After Prior Chemotherapy
September 11, 2026
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
September 10, 2026
